Current Psychiatry Reports

, Volume 12, Issue 5, pp 441–447 | Cite as

What’s New in the Treatment of Cocaine Addiction?

  • Kyle M. Kampman


Cocaine dependence continues to be a significant public health problem in the United States. The number of regular cocaine users has not declined significantly in the United States since 1992. Although counseling remains the treatment of choice for cocaine dependence, many cocaine-dependent patients do not respond completely to standard drug counseling. Therefore, the development of new and more effective treatments for cocaine dependence is a research priority. Progress in the understanding of the neurobiology of cocaine dependence has led to the discovery of several promising medications that have already shown encouraging results in controlled clinical trials. Other promising compounds are just becoming available for clinical trials. The use of novel psychosocial techniques such as contingency management seems to increase the efficacy of several medications used to treat cocaine dependence. New medications and new psychosocial techniques are leading to significant improvements in the treatment of cocaine dependence.


Cocaine Pharmacotherapy Relapse Withdrawal Contingency management 



Dr. Kampman has served as a speaker for Reckitt-Benckiser.


Papers of particular interest, published recently, have been highlighted as: • Of importance ••Of major importance

  1. 1.
    Substance Abuse and Mental Health Services Administration: Treatment Episode Data Set (TEDS): 1994–2004. National Admissions to Substance Abuse Treatment Services. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2006.Google Scholar
  2. 2.
    Ball JK, Albright V: Drug Abuse Warning Network, 2006: national estimates of drug-related emergency department visits. In Substance Abuse and Mental Health Services Administration (SAMHSA), (OAS) OoAS. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2007:8.Google Scholar
  3. 3.
    Caroll K: Behavioral therapies for co-occurring substance use and mood disorders. Biol Psychiatry 2004, 56:778–784.CrossRefGoogle Scholar
  4. 4.
    Touret M, Sallanon-Moulin M, Fages C, et al.: Effects of modafinil-induced wakefulness on glutamine synthetase regulation in the rat brain. Brain Res Mol Brain Res 1994, 26:123–128.CrossRefPubMedGoogle Scholar
  5. 5.
    Dackis C, O’Brien CP: Glutamatergic agents for cocaine dependence. Ann N Y Acad Sci 2003, 1003:328–345.CrossRefPubMedGoogle Scholar
  6. 6.
    Malcolm R, Swayngim K, Donovan JL, et al.: Modafinil and cocaine interactions. Am J Drug Alcohol Abuse 2006, 32:577–587.CrossRefPubMedGoogle Scholar
  7. 7.
    Dackis CA, Lynch KG, Yu E, et al.: Modafinil and cocaine: a double-blind, placebo-controlled drug interaction study. Drug Alcohol Depend 2003, 70:29–37.CrossRefPubMedGoogle Scholar
  8. 8.
    • Hart CL, Haney M, Vosburg SK, et al.: Smoked cocaine self-administration is decreased by modafinil. Neuropsychopharmacology 2008, 3:761–768. In this human laboratory trial, modafinil pretreatment reduced the subjective effects of cocaine and cocaine self-administration among cocaine-dependent individuals. CrossRefGoogle Scholar
  9. 9.
    Dackis C, Kampman K, Lynch K, et al.: A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology 2005, 30:205–211.CrossRefPubMedGoogle Scholar
  10. 10.
    •• Anderson AL, Reid MS, Li SH, et al.: Modafinil for the treatment of cocaine dependence. Drug Alcohol Depend 2009, 104:133–139. This is the most recent and largest clinical trial of modafinil for the treatment of cocaine dependence. The results of this trial suggest that modafinil, in combination with individual behavioral therapy, was effective for increasing cocaine nonuse days in participants without comorbid alcohol dependence, and was effective in reducing cocaine craving. CrossRefPubMedGoogle Scholar
  11. 11.
    Dworkin SI, Smith JE: Neurobehavioral pharmacology of cocaine. In Mechanisms of Cocaine Abuse and Toxicity. Edited by Clouet D, Ashgar K, Brown R. National Institute on Drug Abuse Research Monograph #88. Washington, DC: US Government Printing Office; 1988:185–198.Google Scholar
  12. 12.
    Dewey SL, Chaurasia CS, Chen C, et al.: GABAergic attenuation of cocaine-induced dopamine release and locomoter activity. Synapse 1997, 25:393–398.CrossRefPubMedGoogle Scholar
  13. 13.
    Gerasimov MR, Ashby CR, Gardner EL, et al.: Gamma-vinyl-GABA inhibits methamphetamine, heroin, or ethanol-induced increases in nucleus accumbens dopamine. Synapse 1999, 34:11–19.CrossRefPubMedGoogle Scholar
  14. 14.
    Schmitz B, Schmidt T, Jokiel B, et al.: Visual field constriction in epilepsy patients treated with vigabatrin and other antiepileptic drugs: a prospective study. J Neurol 2002, 249:469–475.CrossRefPubMedGoogle Scholar
  15. 15.
    Manuchehri K, Goodman S, Siviter L, Nightingale S: A controlled study of vigabatrin and visual abnormalities. Br J Ophthalmol 2000, 84:499–505.CrossRefPubMedGoogle Scholar
  16. 16.
    Brodie JD, Figueroa E, Dewey SL, et al.: Treating cocaine addiction: from preclinical to clinical trial experience with gamma-vinyl GABA. Synapse 2003, 50:261–265.CrossRefPubMedGoogle Scholar
  17. 17.
    Brodie JD, Figueroa E, Laska EM, et al.: Safety and efficacy of gamma-vinyl GABA (GVG) for the treatment of methamphetamine and/or cocaine addiction. Synapse 2005, 55:122–125.CrossRefPubMedGoogle Scholar
  18. 18.
    • Brodie JD, Case BG, Figueroa E, et al.: Randomized, double-blind, placebo-controlled trial of vigabatrin for the treatment of cocaine dependence in Mexican parolees. Am J Psychiatry 2009, 166:1269–1277. This was the first double-blind, placebo-controlled trial of vigabatrin for the treatment of cocaine dependence. In this trial, full end-of-trial abstinence was achieved in 14 vigbatrin-treated individuals (28.0%) compared with four in the placebo arm (7.5%). Twelve participants in the vigabatrin group and two in the placebo group maintained abstinence through the follow-up period. CrossRefPubMedGoogle Scholar
  19. 19.
    Petroff OA, Hyder F, Mattson RH, Rothman DL: Topiramate increases brain GABA, homocarnasine, and pyrrolidinone in patients with epilepsy. Neurology 1999, 52:473–478.PubMedGoogle Scholar
  20. 20.
    Gibbs J, Sombati S, DeLorenzo R, Coulter D: Cellular actions of topiramate: blockade of kainate-evoked inward currents in cultured hippocampal neurons. Epilepsia 2000, 41(Suppl 1):S10–S16.CrossRefPubMedGoogle Scholar
  21. 21.
    Cornish JL, Kalivas PW: Glutamate transmission in the nucleus accumbens mediates relapse in cocaine addiction. J Neurosci 2000, 20:1–5.Google Scholar
  22. 22.
    Kampman KM, Pettinati H, Lynch K, et al.: A pilot trial of topiramate for the treatment of cocaine dependence. Drug Alcohol Depend 2004, 75:233–240.CrossRefPubMedGoogle Scholar
  23. 23.
    Hameedi F, Rosen M, McCance-Katz E, et al.: Behavioral, physiological, and pharmacological interaction of cocaine and disulfiram in humans. Biol Psychiatry 1995, 37:560–563.CrossRefPubMedGoogle Scholar
  24. 24.
    Caroll K, Fenton L, Ball S, et al.: Efficacy of disulfiram and cognitive behavioral therapy in cocaine dependent outpatients: a randomized placebo-controlled trial. Arch Gen Psychiatry 2004, 61:264–272.CrossRefGoogle Scholar
  25. 25.
    Caroll K, Nich C, Ball S, et al.: Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram. Addiction 1998, 93:713–727.CrossRefGoogle Scholar
  26. 26.
    George T, Chawarski M, Pakes J, et al.: Disulfiram versus placebo for cocaine dependence in buprenorphine-maintained subjects: a preliminary trial. Biol Psychiatry 2000, 47:1080–1086.CrossRefPubMedGoogle Scholar
  27. 27.
    Petrakis I, Caroll K, Nich C, et al.: Disulfiram treatment for cocaine dependence in methadone-maintained opioid addicts. Addiction 2000, 95:219–228.CrossRefPubMedGoogle Scholar
  28. 28.
    • Pettinati HM, Kampman KM, Lynch KG, et al.: A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence. Addict Behav 2008, 33:651–667. In this trial, naltrexone, disulfiram, and the combination of these medications were compared with placebo for the treatment of cocaine and alcohol dependence. In the primary analyses (generalized estimating equation modeling), abstinence from cocaine as measured by cocaine-negative urines and days of self-reported abstinence from cocaine or alcohol did not differ between placebo and any of the medication groups. However, patients taking disulfiram (alone or in combination) were most likely to achieve combined abstinence from cocaine and alcohol. Secondary analyses revealed that patients taking the disulfiram–naltrexone combination were most likely to achieve 3 consecutive weeks of abstinence from cocaine and alcohol. CrossRefPubMedGoogle Scholar
  29. 29.
    Kantak K, Collins S, Lipman E, et al.: Evaluation of anti-cocaine antibodies and a cocaine vaccine in a rat self-administration model. Psychopharmacology (Berl) 2000, 148:251–262.CrossRefGoogle Scholar
  30. 30.
    Kosten T, Rosen M, Bond J, et al.: Human therapeutic cocaine vaccine: safety and immunogenicity. Vaccine 2002, 20:1196–1204.CrossRefPubMedGoogle Scholar
  31. 31.
    Martell B, Mitchell E, Poling J, et al.: Vaccine pharmacotherapy for the treatment of cocaine dependence. Biol Psychiatry 2005, 58:158–164.CrossRefPubMedGoogle Scholar
  32. 32.
    •• Martell BA, Orson FM, Poling J, et al.: Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: a randomized, double-blind, placebo-controlled efficacy trial. Arch Gen Psychiatry 2009, 66:1116–1123. In this trial, 115 cocaine-dependent patients were randomly assigned to receive a vaccine that stimulated the production of anticocaine antibodies or placebo. The 21 vaccinated patients (38%) who attained serum IgG anticocaine antibody levels of 43 μg/mL or higher (i.e., high IgG level) had significantly more cocaine-free urine samples than those with levels less than 43 μg/mL (i.e., low IgG level) and the placebo-receiving patients during weeks 9 to 16 (45% vs. 35% cocaine-free urine samples, respectively). The proportion of patients having a 50% reduction in cocaine use was significantly greater in those with a high IgG level than in those with a low IgG level (53% vs. 23% of patients, respectively; P = 0.048). CrossRefPubMedGoogle Scholar
  33. 33.
    Mantyh PW, Hunt SP, Maggio JE: Substance P receptors: localization by light microscopic autoradiography in rat brain using [3H]SP as the radioligand. Brain Res 1984, 307:147–165.CrossRefPubMedGoogle Scholar
  34. 34.
    Holmes A, Heilig M, Rupniak NMJ, et al.: Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders.[see comment]. Trends Pharmacol Sci 2003, 24:580–588.CrossRefPubMedGoogle Scholar
  35. 35.
    Sinha R, Garcia M, Paliwal P, et al.: Stress-induced cocaine craving and hypothalamic-pituitary-adrenal responses are predictive of cocaine relapse outcomes. Arch Gen Psychiatry 2006, 63:324–331.CrossRefPubMedGoogle Scholar
  36. 36.
    Kampman KM, Volpicelli JR, Mulvaney FD, et al.: Cocaine withdrawal severity and urine toxicology results from treatment entry predict outcome in medication trials for cocaine dependence. Addict Behav 2002, 27:251–260.CrossRefPubMedGoogle Scholar
  37. 37.
    Heidbreder CA, Gardner EL, Xi Z-X, et al.: The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence. Brain Res Brain Res Rev 2005, 49:77–105.CrossRefPubMedGoogle Scholar
  38. 38.
    Sokoloff P, Diaz J, Le Foll B, et al.: The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders. CNS Neurol Disord Drug Targets 2006, 5:25–43.CrossRefPubMedGoogle Scholar
  39. 39.
    Vorel SR, Ashby CR Jr, Paul M, et al.: Dopamine D3 receptor antagonism inhibits cocaine-seeking and cocaine-enhanced brain reward in rats. J Neurosci 2002, 22:9595–9603.PubMedGoogle Scholar
  40. 40.
    Di Ciano P, Underwood RJ, Hagan JJ, Everitt BJ: Attenuation of cue-controlled cocaine-seeking by a selective D3 dopamine receptor antagonist SB-277011-A. Neuropsychopharmacology 2003, 28:329–338.CrossRefPubMedGoogle Scholar
  41. 41.
    Xi Z-X, Newman AH, Gilbert JG, et al.: The novel dopamine D3 receptor antagonist NGB 2904 inhibits cocaine’s rewarding effects and cocaine-induced reinstatement of drug-seeking behavior in rats. Neuropsychopharmacology 2006, 31:1393–1405.CrossRefPubMedGoogle Scholar
  42. 42.
    Xi Z-X, Gilbert J, Campos AC, et al.: Blockade of mesolimbic dopamine D3 receptors inhibits stress-induced reinstatement of cocaine-seeking in rats. Psychopharmacology 2004, 176:57–65.CrossRefPubMedGoogle Scholar
  43. 43.
    Kalivas PW, Volkow ND: The neural basis of addiction: a pathology of motivation and choice. Am J Psychiatry 2005, 162:1403–1413.CrossRefPubMedGoogle Scholar
  44. 44.
    Baker D, McFarland K, Lake R, et al.: N-acetyl cysteine-induced blockade of cocaine-induced reinstatement. Ann N Y Acad Sci 2003, 1003:349–351.CrossRefPubMedGoogle Scholar
  45. 45.
    • LaRowe SD, Myrick H, Hedden S, et al.: Is cocaine desire reduced by N-acetylcysteine? Am J Psychiatry 2007, 164:1115–1117. In this double-blind, placebo-controlled trial, 15 participants received NAC or placebo during a 3-day hospitalization. Participants were crossed over to receive the opposite condition on a second, identical 3-day stay occurring 4 days later. During each hospital stay, participants completed a cue reactivity procedure that involved collecting psychophysical and subjective data in response to slides depicting cocaine and cocaine use. While taking NAC, participants reported less desire to use and less interest in response to cocaine slides and watched cocaine slides for less time. NAC may be useful in reducing cocaine craving. CrossRefPubMedGoogle Scholar
  46. 46.
    LaRowe SD, Mardikian P, Malcolm R, et al.: Safety and tolerability of N-acetylcysteine in cocaine-dependent individuals. Am J Addict 2006, 15:105–110.CrossRefPubMedGoogle Scholar
  47. 47.
    Higgins ST, Budney AJ, Bickel WK, et al.: Incentives improve outcome in outpatient behavioral treatment of cocaine dependence. Arch Gen Psychiatry 1994, 51:568–576.PubMedGoogle Scholar
  48. 48.
    Kosten T, Oliveto A, Feingold A, et al.: Desipramine and contingency management for cocaine and opiate dependence in buprenorphine maintained patients. Drug Alcohol Depend 2003, 70:315–325.CrossRefPubMedGoogle Scholar
  49. 49.
    Poling J, Oliveto A, Petry N, et al.: Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population. Arch Gen Psychiatry 2006, 63:219–228.CrossRefPubMedGoogle Scholar
  50. 50.
    • Moeller FG, Schmitz JM, Steinberg JL, et al.: Citalopram combined with behavioral treatment reduces cocaine use: a double-blind, placebo-controlled trial. Am J Drug Alcohol Abuse 2007, 33:367–378. The purpose of this study was to examine whether the SSRI citalopram would reduce cocaine-positive urines in a 12-week, double-blind, placebo-controlled trial. Seventy-six cocaine-dependent patients received citalopram, 20 mg/d, or placebo along with cognitive-behavioral therapy and contingency management. Citalopram-treated patients showed a significant reduction in cocaine-positive urines during treatment compared with placebo-treated patients. CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Department of PsychiatryUniversity of Pennsylvania School of Medicine, University of Pennsylvania Treatment Research CenterPhiladelphiaUSA

Personalised recommendations